Iron Chelation Therapy in the Management of Thalassemia: the Asian Perspectives

Overview

Journal Int J Hematol

Specialty Hematology

Date 2009 Oct 29

PMID 19862602

Citations 28

Authors

Vip Viprakasit

Chan Lee-Lee

Quah Thuan Chong

Kai-Hsin Lin

Archrob Khuhapinant

Affiliations

Soon will be listed here.

Abstract

Worldwide, thalassemia is the most commonly inherited hemolytic anemia, and it is most prevalent in Asia and the Middle East. Iron overload represents a significant problem in patients with transfusion-dependent beta-thalassemia. Chelation therapy with deferoxamine has traditionally been the standard therapeutic option but its usage is tempered by suboptimal patient compliance due to the discomfort and demands associated with the administration regimen. Therefore, a great deal of attention has been focused on the development of oral chelating agents. Deferiprone, even though available for nearly two decades in Asia with recent encouraging data on cardiac iron removal and long-term efficacy, has serious adverse effects including agranulocytosis and neutropenia which has impeded it from routine clinical practice. A novel oral chelator; deferasirox is effective throughout a 24 h dosing period and both preclinical and clinical data indicate that it successfully removes both hepatic and cardiac iron. In Asia, optimal management of severe thalassemia patients and the availability and access to oral iron chelators still presents a major challenge in many countries. In this regard, the development and implementation of consensus guidelines for management of Asian patients with transfusion-dependent thalassemia will be a major step towards improving and maintaining the continuity of patient care.

Citing Articles

Iron chelating, antioxidant, and anti-inflammatory properties of brazilin from Linn.

Taveepanich S, Chayajarus K, Jittimanee J, Phusri N, Thongdee P, Sawatdee K Heliyon. 2024; 10(19):e38213.

PMID: 39397930 PMC: 11470788. DOI: 10.1016/j.heliyon.2024.e38213.

Skin complications during iron chelation therapy for beta-thalassemia: overview and treatment approach.

Saeidnia M, Shadfar F, Sharifi S, Babashahi M, Ghaderi A, Shokri M Int J Hematol. 2024; 120(3):271-277.

PMID: 39088188 DOI: 10.1007/s12185-024-03825-w.

Justification of Universal Iron Supplementation for Infants 6-12 months in Regions with a High Prevalence of Thalassemia.

Sinlapamongkolkul P, Surapolchai P, Viprakasit V Mediterr J Hematol Infect Dis. 2023; 15(1):e2023056.

PMID: 37705528 PMC: 10497306. DOI: 10.4084/MJHID.2023.056.

Effects of green tea extract treatment on erythropoiesis and iron parameters in iron-overloaded β-thalassemic mice.

Settakorn K, Kongkarnka S, Chompupoung A, Svasti S, Fucharoen S, Porter J Front Physiol. 2023; 13:1053060.

PMID: 36620219 PMC: 9816339. DOI: 10.3389/fphys.2022.1053060.

Effect of drug use calendar on adherence to iron chelation therapy in young thalassemia patients.

Chawsamtong S, Jetsrisuparb A, Kengkla K, Jaisue S Pharm Pract (Granada). 2022; 20(1):2570.

PMID: 35497900 PMC: 9014910. DOI: 10.18549/PharmPract.2022.1.2570.

References

Wood J, Otto-Duessel M, Gonzalez I, Aguilar M, Shimada H, Nick H . Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil. Transl Res. 2006; 148(5):272-80. PMC: 2896322. DOI: 10.1016/j.trsl.2006.05.005. View

Borgna-Pignatti C . Surviving with thalassemia major: the Italian experience. Pediatr Hematol Oncol. 2006; 24(1):75-8. DOI: 10.1080/08880010601001461. View

Viprakasit V, Tanphaichitr V, Mahasandana C, Assteerawatt A, Suwantol L, Veerakul G . Linear growth in homozygous beta-thalassemia and beta-thalassemia/hemoglobin E patients under different treatment regimens. J Med Assoc Thai. 2002; 84(7):929-41. View

Wood J, Enriquez C, Ghugre N, Tyzka J, Carson S, Nelson M . MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood. 2005; 106(4):1460-5. PMC: 1895207. DOI: 10.1182/blood-2004-10-3982. View

Hershko C, Link G, Konijn A, Cabantchik Z . Objectives and mechanism of iron chelation therapy. Ann N Y Acad Sci. 2005; 1054:124-35. DOI: 10.1196/annals.1345.015. View

Cappellini M, Bejaoui M, Agaoglu L, Porter J, Coates T, Jeng M . Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia. Clin Ther. 2007; 29(5):909-917. DOI: 10.1016/j.clinthera.2007.05.007. View

Luk C, Ling S, Chik K, Yuen H, Li C, Shing M . Morbidity and mortality patterns of thalassaemia major patients in Hong Kong: retrospective study. Hong Kong Med J. 2002; 8(4):255-60. View

Naithani R, Chandra J, Sharma S . Safety of oral iron chelator deferiprone in young thalassaemics. Eur J Haematol. 2005; 74(3):217-20. DOI: 10.1111/j.1600-0609.2004.00377.x. View

Fucharoen S, Winichagoon P . Clinical and hematologic aspects of hemoglobin E beta-thalassemia. Curr Opin Hematol. 2000; 7(2):106-12. DOI: 10.1097/00062752-200003000-00006. View

10.

Mazza P, Giua R, De Marco S, Bonetti M, Amurri B, MASI C . Iron overload in thalassemia: comparative analysis of magnetic resonance imaging, serum ferritin and iron content of the liver. Haematologica. 1995; 80(5):398-404. View

11.

Agarwal M . Exjade (ICL 670): A new oral iron chelator. J Assoc Physicians India. 2006; 54:214-7. View

12.

Galanello R, Piga A, Forni G, Bertrand Y, Foschini M, Bordone E . Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major. Haematologica. 2006; 91(10):1343-51. View

13.

Viprakasit V, Kidd A, Ayyub H, Horsley S, Hughes J, Higgs D . De novo deletion within the telomeric region flanking the human alpha globin locus as a cause of alpha thalassaemia. Br J Haematol. 2003; 120(5):867-75. DOI: 10.1046/j.1365-2141.2003.04197.x. View

14.

Lee A, Ha S, Wong K, Cheng M, Ip P, Chan G . Prevention of beta-thalassemia major by antenatal screening in Hong Kong. Pediatr Hematol Oncol. 1998; 15(3):249-54. DOI: 10.3109/08880019809028792. View

15.

Cohen A, Galanello R, Pennell D, Cunningham M, Vichinsky E . Thalassemia. Hematology Am Soc Hematol Educ Program. 2004; :14-34. DOI: 10.1182/asheducation-2004.1.14. View

16.

Hershko C, Konijn A, Nick H, Breuer W, Cabantchik Z, Link G . ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture. Blood. 2001; 97(4):1115-22. DOI: 10.1182/blood.v97.4.1115. View

17.

Cohen A . New advances in iron chelation therapy. Hematology Am Soc Hematol Educ Program. 2006; :42-7. DOI: 10.1182/asheducation-2006.1.42. View

18.

Pakbaz Z, Fischer R, Fung E, Nielsen P, Harmatz P, Vichinsky E . Serum ferritin underestimates liver iron concentration in transfusion independent thalassemia patients as compared to regularly transfused thalassemia and sickle cell patients. Pediatr Blood Cancer. 2007; 49(3):329-32. DOI: 10.1002/pbc.21275. View

19.

Porter J . Monitoring and treatment of iron overload: state of the art and new approaches. Semin Hematol. 2005; 42(2 Suppl 1):S14-8. DOI: 10.1053/j.seminhematol.2005.01.004. View

20.

Peng C, Chow K, Chen J, Chiang Y, Lin T, Tsai C . Safety monitoring of cardiac and hepatic systems in beta-thalassemia patients with chelating treatment in Taiwan. Eur J Haematol. 2003; 70(6):392-7. DOI: 10.1034/j.1600-0609.2003.00071.x. View